{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:13:16Z","timestamp":1778659996624,"version":"3.51.4"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2026,5,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>&lt;P&gt;The CRISPR-Cas system has significantly advanced genome editing, offering superior\nefficiency, precision, and ease of use compared to traditional technologies such as Zinc Finger\nNucleases (ZFNs) and Transcription Activator-Like Effector Nucleases (TALENs). CHO cells are\na widely used mammalian cell line for large-scale therapeutic protein manufacturing due to their\nability to produce human-like glycosylation patterns and grow in serum-free media. Recent\nCRISPR-based CHO cell engineering enables precise genetic modifications, improving productivity, stability, scalability, and reducing costs.\nThis article highlights the transformative role of CRISPR technologies in addressing genetic disorders and expanding the frontiers of multiple scientific fields. It offers a comprehensive analysis\nof several CRISPR-Cas systems, including Cas9, Cas12, Cas13, and Cas14, emphasizing their\nunique structural features and functional capabilities. While Cas9 has dominated many genomeediting applications, the use of Cas13 in Chinese Hamster Ovary (CHO) cells has opened up\npromising RNA-targeting strategies. Moreover, the compact Cas14 system presents notable potential for applications requiring ultra-precise genome manipulation.\nWith their critical role in therapeutic protein production, CHO cells have greatly benefited from\nCRISPR-enabled engineering, leading to measurable improvements in productivity, stability, and\ncost-efficiency. Key advancements in CRISPR delivery platforms, including both viral and nonviral vectors, are discussed alongside ongoing challenges such as off-target effects and regulatory\nconsiderations. Emerging trends such as base editing, prime editing, and the integration of artificial intelligence for system optimization are also explored. Altogether, the discussion underscores\nthe pivotal contribution of CRISPR technologies to CHO cell engineering and their broader impact on the future of biopharmaceutical manufacturing<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113892010408149251016112221","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:49:01Z","timestamp":1778658541000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRISPR-Cas Systems and CHO in Biopharmaceuticals: Unlocking New\nPossibilities in Gene Editing"],"prefix":"10.2174","volume":"27","author":[{"given":"Soofia","family":"Sorourian","sequence":"first","affiliation":[{"name":"Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz Universityof Medical Sciences, Shiraz, 71348-14336, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas Behzad","family":"Behbahani","sequence":"additional","affiliation":[{"name":"Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz Universityof Medical Sciences, Shiraz, 71348-14336, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010408149251016112221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/253454\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010408149251016112221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:49:24Z","timestamp":1778658564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/253454\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892010408149251016112221","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}